Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Frontiers in Pharmacology
|
September 5, 2022
Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysis
Salomé Martin, Brahim Azzouz, Aurore Morel, et al.
Expert Opinion on Drug Safety
|
December 18, 2020
Drug induced stuttering: pharmacovigilance data
Thierry Trenque, Aurore Morel, Agathe Trenque, et al.
Fundamental & Clinical Pharmacology
|
June 18, 2016
Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database
Paul de Boissieu, Louise Gaboriau, Aurore Morel, et al.
Expert Opinion on Drug Safety
|
August 4, 2018
Psoriasis during angiotensin receptor blocker exposure: an underestimated adverse drug reaction
Brahim Azzouz, Malak Abou Taam, Aurore Morel, et al.
European Journal of Clinical Pharmacology
|
January 7, 2022
Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity
Thierry Trenque, Elise Lepoix, Agathe Trenque, et al.
Therapie
|
June 5, 2021
[DRESS syndrome to phenobarbital: A hypersensitivity reaction to drugs known but forgotten by prescribers-A case report]
Camille Douilly, Elise Lepoix, Brahim Azzouz, et al.
Drug Safety
|
October 11, 2019
Psoriasis After Exposure to Angiotensin-Converting Enzyme Inhibitors: French Pharmacovigilance Data and Review of the Literature
Brahim Azzouz, Aurore Morel, Lukshe Kanagaratnam, et al.
Frontiers in Pediatrics
|
May 19, 2018
Overview of Social Cognitive Dysfunctions in Rare Developmental Syndromes With Psychiatric Phenotype
Aurore Morel, Elodie Peyroux, Arnaud Leleu, et al.
Therapie
|
May 24, 2018
Eosinophilic pneumonia induced by non-steroidal anti-inflammatory drugs: An underestimated risk
François Krabansky, Brahim Azzouz, Josette Biya, et al.
British Journal of Clinical Pharmacology
|
March 30, 2022
Psoriasis risk after beta-blocker exposure: Description of a pharmacovigilance signal
Brahim Azzouz, Apolline De Guizelin, Aude Lambert, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Frontiers in Pharmacology
|
September 5, 2022
Anti-NMDA receptor encephalitis and vaccination: A disproportionality analysis
Salomé Martin, Brahim Azzouz, Aurore Morel, et al.
Expert Opinion on Drug Safety
|
December 18, 2020
Drug induced stuttering: pharmacovigilance data
Thierry Trenque, Aurore Morel, Agathe Trenque, et al.
Fundamental & Clinical Pharmacology
|
June 18, 2016
Bisphosphonate-related osteonecrosis of the jaw: data from the French national pharmacovigilance database
Paul de Boissieu, Louise Gaboriau, Aurore Morel, et al.
Expert Opinion on Drug Safety
|
August 4, 2018
Psoriasis during angiotensin receptor blocker exposure: an underestimated adverse drug reaction
Brahim Azzouz, Malak Abou Taam, Aurore Morel, et al.
European Journal of Clinical Pharmacology
|
January 7, 2022
Immune-mediated necrotizing myopathy with pembrolizumab: a specific neuromuscular entity
Thierry Trenque, Elise Lepoix, Agathe Trenque, et al.
Therapie
|
June 5, 2021
[DRESS syndrome to phenobarbital: A hypersensitivity reaction to drugs known but forgotten by prescribers-A case report]
Camille Douilly, Elise Lepoix, Brahim Azzouz, et al.
Drug Safety
|
October 11, 2019
Psoriasis After Exposure to Angiotensin-Converting Enzyme Inhibitors: French Pharmacovigilance Data and Review of the Literature
Brahim Azzouz, Aurore Morel, Lukshe Kanagaratnam, et al.
Frontiers in Pediatrics
|
May 19, 2018
Overview of Social Cognitive Dysfunctions in Rare Developmental Syndromes With Psychiatric Phenotype
Aurore Morel, Elodie Peyroux, Arnaud Leleu, et al.
Therapie
|
May 24, 2018
Eosinophilic pneumonia induced by non-steroidal anti-inflammatory drugs: An underestimated risk
François Krabansky, Brahim Azzouz, Josette Biya, et al.
British Journal of Clinical Pharmacology
|
March 30, 2022
Psoriasis risk after beta-blocker exposure: Description of a pharmacovigilance signal
Brahim Azzouz, Apolline De Guizelin, Aude Lambert, et al.
Page
of 2